Follicular Lymphoma — Trials

Follicular Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

775 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 216
Recruiting: 107
Ph III recruiting: 10
Growth YoY: −8.6%
Industry share: 29%
Top sponsor: City of Hope Medical Center
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (149)

clinicaltrialsPublishedShowing 51–100 of 123 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05455697	Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma	active not recruiting	Phase 1 / Phase 2	33	University of WashingtonOTHER	1	Jun 22, 2026	clinicaltrials
NCT03162536	A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)	active not recruiting	Phase 1 / Phase 2	190	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)